Lytix Biopharma today announces that Torbjørn Furuseth has stepped down as Chief Financial Officer. Gjest Breistein, who has served as Business Controller in Lytix Biopharma since August 2017, will succeed him.

Mr. Breistein has eight years of experience from PwC as an auditor and consultant in the capital markets group advising clients in capital market transactions, financing and listing processes. Mr. Breistein is a state authorized public accountant, and he holds a master in applied economics and finance from Copenhagen Business School and a master in professional accountancy from BI Norwegian School of Management.  

“Edwin Klumper, CEO of Lytix Biopharma commented: Gjest has proven to be a great contributor to Lytix with his strong financial and transaction background. I am impressed by how he mastered so quickly the highly complex, innovative and volatile immune therapy market space since he joined Lytix. The management team is looking forward to jointly realizing Lytix’ strategy - bringing more cancer patients to benefit from immune therapy and delivering value to its shareholders.”

Dr. Klumper added: “On behalf of the company we thank Torbjørn for his significant contributions and commitment to Lytix. He has been a strong team player providing excellent strategic and financial leadership. Lytix is grateful that Torbjørn contributed through a challenging period for the company. He leaves Lytix with a legacy of creating a solid business base for future development. We will miss his camaraderie and wish him every success in future opportunities.”